Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diazoxide choline controlled release - Soleno Therapeutics

Drug Profile

Diazoxide choline controlled release - Soleno Therapeutics

Alternative Names: C601; C602; DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release; Diazoxide-choline-controlled-release-Essentialis

Latest Information Update: 10 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Essentialis
  • Developer Essentialis; Soleno Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Obesity therapies; Peripheral vasodilators; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Glycogen storage disease type I
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prader-Willi syndrome
  • Phase II Hypertriglyceridaemia
  • Discontinued Hypoglycaemia; Obesity

Most Recent Events

  • 04 Oct 2023 Soleno Therapeutics completes an open-label extension phase III trial for Prader-Willi syndrome (In adolescents, In adults, In children) in USA and UK (NCT03714373) (EudraCT2018-004216-22)
  • 26 Sep 2023 Soleno Therapeutics announces intention to submit new drug application to US FDA for Prader-Willi syndrome in mid-year 2024
  • 26 Sep 2023 Topline efficacy and adverse events data from a phase III trial in Prader-Willi syndrome released by Soleno Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top